A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

  • STATUS
    Recruiting
  • End date
    Sep 30, 2024
  • participants needed
    180
  • sponsor
    Seagen Inc.
Send
Updated on 19 December 2020
See if I qualify
lymphoma
hodgkin's disease
measurable disease
chemotherapy regimen
nivolumab
dacarbazine
t-cell lymphoma
peripheral t-cell lymphoma
brentuximab vedotin
bendamustine
brentuximab
classical hodgkin lymphoma

Summary

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.

Description

This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as monotherapy and in combination with other agents as frontline therapy. There are 6 parts of the study. The population to be studied includes treatment-nave patients with classical Hodgkin lymphoma (HL) or treatment-nave patients with CD30-expressing peripheral T-cell lymphoma (PTCL).

Details
Treatment Nivolumab, Bendamustine, dacarbazine, brentuximab vedotin
Clinical Study IdentifierNCT01716806
SponsorSeagen Inc.
Last Modified on19 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: T-Cell Lymphoma or Peripheral T-Cell Lymphoma or Hodgkin's Disease or Lymphoma?
Do you have any of these conditions: Peripheral T-Cell Lymphoma or hodgkin lymphomas or Lymphoma or hodgkins lymphoma or hodgkin's lymphomas or Hodgkin's Disease or hodgkin's lymphoma or ...?
Do you have any of these conditions: Peripheral T-Cell Lymphoma or hodgkin's lymphomas or Hodgkin's Disease or hodgkins lymphoma or Lymphoma or hodgkin or T-Cell Lymphoma or hodgkin's lym...?
Do you have any of these conditions: Lymphoma or hodgkin's lymphoma or Hodgkin's Disease or hodgkin or hodgkins lymphoma or hodgkin lymphomas or T-Cell Lymphoma or hodgkin's lymphomas or ...?
Do you have any of these conditions: hodgkin's lymphoma or hodgkins lymphoma or Lymphoma or T-Cell Lymphoma or Hodgkin's Disease or hodgkin lymphomas or Peripheral T-Cell Lymphoma or hodg...?
Parts A, B, C, and D: 60 years of age or older
Treatment-naive patients with histopathological diagnosis of classical Hodgkin lymphoma (Parts A, B, C, D, and E)
Treatment-naive patients with CD30-expressing PTCL (Part F)
Ineligible for or have declined initial conventional combination chemotherapy for HL (Parts A, B, C, and D)
Unsuitable or unfit for initial conventional combination chemotherapy for HL (Part E) or CD30-expressing PTCL due to the presence of comorbidity-factors, as documented by
A CIRS score of 10 or greater
Requiring assistance with or dependence on other for any instrumental activities of daily living (IADLs)
Measurable disease of at least 1.5 cm as documented by radiographic technique
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3 (Parts, A, B, C, E, and F) or less than or equal to 2 (Part D)

Exclusion Criteria

Symptomatic neurologic disease compromising IADLs or requiring medication
History of progressive multifocal leukoencephalopathy
Grade 3 or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of brentuximab vedotin
Concurrent use of other investigational agents
Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drug
History of another malignancy within 1 year before first dose of study drug (Parts E and F only)
Part D only
Received any prior immune-oncology therapy
History of known or suspected autoimmune disease
Prior allogeneic stem cell transplant
History of cerebral vascular event within 6 months of first dose of study drug
Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicology
Known history of pancreatitis
Parts D, E, and F only
Known cerebral/meningeal disease related to the underlying malignancy
Systemic treatment with corticosteroids or other immunosuppressive medications within 1 week of enrollment
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name
Edit Delete

Annotated by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet